Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
Holding AVTX?
Track your performance easily
AVTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.01 - $34.46
Previous CloseN/A
Volume10.82K
Average Volume (3M)131.78K
Market Cap
$78.90M
Enterprise Value$23.84M
Total Cash (Recent Filing)$5.13M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Mar 27, 2025EPS Estimate
-1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-168.23
Shares Outstanding10,463,633
10 Day Avg. Volume93,175
30 Day Avg. Volume131,785
Standard Deviation0.60
R-Squared0.00670
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)95.57
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue29.07
Enterprise Value/Gross Profit37.25
Enterprise Value/Ebitda0.33
Forecast
1Y Price Target
$33.00Price Target Upside334.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Avalo Therapeutics News
PremiumCompany Announcements
Avalo Therapeutics Appoints New Chief Strategy Officer
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAVTX-009 is currently in a Phase 2b trial in hidradenitis suppurativa with significant upside potential, and AVTX is trading at less than a $200M enterprise value.
Market GrowthThe market for hidradenitis suppurativa is expected to grow significantly, with AVTX-009 having high odds of showing greater activity than existing treatments.
Product PotentialAVTX-009 is believed to have best-in-class features that could support preferred positioning in several large inflammatory and autoimmune indications.
Bears Say
EarningsThe company reported a significantly larger than expected loss per share, which could indicate underlying financial challenges.
Financial PerformanceEarnings per share were more than three times lower than analyst estimates, highlighting potential issues with cost management or revenue generation.
RevenueTotal revenues were reported to be minimal, suggesting difficulties in achieving substantial sales or market penetration.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVTX FAQ
What was Avalo Therapeutics’s price range in the past 12 months?
Avalo Therapeutics lowest stock price was $4.01 and its highest was $34.46 in the past 12 months.
What is Avalo Therapeutics’s market cap?
Avalo Therapeutics’s market cap is $78.90M.
When is Avalo Therapeutics’s upcoming earnings report date?
Avalo Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 55 days.
How were Avalo Therapeutics’s earnings last quarter?
Avalo Therapeutics released its earnings results on Nov 07, 2024. The company reported -$2.83 earnings per share for the quarter, missing the consensus estimate of -$1.19 by -$1.64.
Is Avalo Therapeutics overvalued?
According to Wall Street analysts Avalo Therapeutics’s price is currently Undervalued.
Does Avalo Therapeutics pay dividends?
Avalo Therapeutics does not currently pay dividends.
What is Avalo Therapeutics’s EPS estimate?
Avalo Therapeutics’s EPS estimate is -1.42.
How many shares outstanding does Avalo Therapeutics have?
Avalo Therapeutics has 10,463,633 shares outstanding.
What happened to Avalo Therapeutics’s price movement after its last earnings report?
Avalo Therapeutics reported an EPS of -$2.83 in its last earnings report, missing expectations of -$1.19. Following the earnings report the stock price went down -3.657%.
Which hedge fund is a major shareholder of Avalo Therapeutics?
Among the largest hedge funds holding Avalo Therapeutics’s share is RA Capital Management. It holds Avalo Therapeutics’s shares valued at 9M.
---
Avalo Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (334.21% Upside)
$33.00 (334.21% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $12.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
69.81%
12-Months-Change
Fundamentals
Return on Equity
-42.52%
Trailing 12-Months
Asset Growth
236.37%
Trailing 12-Months
Company Description
Avalo Therapeutics
Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher and Solomon H. Snyder on January 31, 2011 and is headquartered in Baltimore, MD.
---
AVTX Stock 12 Month Forecast
Average Price Target
$33.00
▲(334.21% Upside)
Technical Analysis
Synlogic
―
Corvus Pharmaceuticals
―
X4 Pharmaceuticals
―
Meiragtx Holdings
―
Kezar Life Sciences
―
Best Analysts Covering AVTX
1 Year
1 Year Success Rate
3/18 ratings generated profit
1 Year Average Return
-41.09%
reiterated a buy rating 3 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -41.09% per trade.
---